FDA Advises Restricting
Use of Fluoroquinolone
FDA is advising that the serious side effects associated
with fluoroquinolone antibacterial drugs generally outweigh
the benefits for patients with sinusitis, bronchitis, and
uncomplicated urinary tract infections who have other treatment
options. For patients with these conditions,
fluoroquinolones should be reserved for those who
do not have alternative treatment options.
Read more at: http://bit.do/b4LSH
Dr. Reddy’s Acquires Six
Dr. Reddy’s Laboratories Ltd. announced the acquisition of
an eminent portfolio of over-the-counter (OTC) brands in the
cough-and-cold, pain, and dermatology categories.
The company acquired six OTC brands from
Read more at: http://bit.do/b4LSS
IDA, reveals the
Ireland and the
for the country’s
future in the
to IPHA (Irish
Pharmaceutical Healthcare Association), “Ireland is one of the
leading locations for the pharmaceutical industry in Europe.” With
a population of 4. 5 million people, Ireland boasts approximately
120 plants from overseas companies, including nine
of the 10 big pharma companies—most of whom have
operated in Ireland since the 1960s.
Read more at: http://bit.do/b4LSG
Ireland Emerges as New Hub
for Biotech Investments
FDA Warning: Antipsychotic
Drug May Lead to Urges to
Gamble, Binge Eat, Shop, &
Grange Castle Aerial. Photo courtesy of IDA Ireland.
FDA is warning that compulsive or uncontrollable urges
to gamble, binge eat, shop, and have sex have been
reported with the use of the antipsychotic drug aripiprazole
(Abilify, Abilify Maintena, Aristada, and generics). These
uncontrollable urges were reported to have stopped when
the medicine was discontinued or the dose was reduced.
These impulse-control problems are rare, but
they may result in harm to the patient and
others if not recognized.
Read more at: http://bit.do/b4LSQ